Valuation: Galapagos NV

Market Cap 177.26Cr 202.77Cr 202.77Cr 162.9Cr 151.85Cr 288.01Cr 19TCr 292.38Cr 1.96TCr 760.27Cr 9.49TCr 761.12Cr 744.78Cr 33TCr P/E 2026 *
-9.25x
P/E 2027 * -10.7x
Enterprise Value -88Cr -100.87Cr -100.87Cr -81Cr -76Cr -143.27Cr -9.6TCr -145.45Cr -972.89Cr -378.21Cr -4.72TCr -378.63Cr -370.5Cr -16TCr EV / Sales 2026 *
-5.86x
EV / Sales 2027 * -5.09x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 13/05/2025
Director of Finance/CFO 43 07/07/2025
Chief Tech/Sci/R&D Officer 61 08/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 13/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
+1.70%+7.41%+3.12%+8.46% 4.99TCr
+0.92%+3.93%+399.71%+605.33% 4.02TCr
+1.89%+8.32%+26.06%-6.35% 3.46TCr
+2.38%+6.35%+21.25%+64.58% 3.31TCr
+3.96%+10.67%+11.89%+38.86% 2.75TCr
+2.51%+5.27% - - 1.7TCr
+2.58%+5.79%+73.44%+133.27% 1.59TCr
+0.32%+0.58%+13.67%+19.09% 1.39TCr
+3.30%+0.76%+90.23%+99.12% 1.35TCr
Average +2.17%+5.82%+79.92%+120.30% 2.73TCr
Weighted average by Cap. +2.07%+6.53%+90.75%+137.74%

Financials

2026 *2027 *
Net sales 15Cr 17Cr 17Cr 14Cr 13Cr 24Cr 1.64TCr 25Cr 166Cr 65Cr 805.55Cr 65Cr 63Cr 2.78TCr 13Cr 15Cr 15Cr 12Cr 11Cr 21Cr 1.44TCr 22Cr 145.76Cr 57Cr 707.31Cr 57Cr 56Cr 2.44TCr
Net income -26Cr -30Cr -30Cr -24Cr -22Cr -42Cr -2.84TCr -43Cr -287.67Cr -111.83Cr -1.4TCr -111.95Cr -109.55Cr -4.81TCr -15Cr -17Cr -17Cr -13Cr -12Cr -24Cr -1.58TCr -24Cr -160.16Cr -62Cr -777.21Cr -62Cr -61Cr -2.68TCr
Net Debt -265.44Cr -303.64Cr -303.64Cr -243.94Cr -227.38Cr -431.28Cr -29TCr -437.82Cr -2.93TCr -1.14TCr -14TCr -1.14TCr -1.12TCr -49TCr -244.49Cr -279.67Cr -279.67Cr -224.69Cr -209.43Cr -397.24Cr -27TCr -403.26Cr -2.7TCr -1.05TCr -13TCr -1.05TCr -1.03TCr -45TCr
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
B